Tessa C C Jaspers
Overview
Explore the profile of Tessa C C Jaspers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
15
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Uden R, Jaspers T, Meijer K, van Stralen K, Maat B, Khorsand N, et al.
Thromb Res
. 2024 Feb;
236:4-13.
PMID: 38377636
Background: Guidelines advise 50 % and 25 % dose reduction of the therapeutic nadroparin dose (86 IU/kg) in patients with eGFR 15-29 and 30-60 ml/min respectively. For monitoring, peak anti-Xa...
2.
Workum J, Keyany A, Jaspers T
Toxicol Rep
. 2023 Jul;
11:141-144.
PMID: 37520772
Introduction: Severe metformin overdose can result in life-threatening conditions such as metabolic acidosis with hyperlactatemia and vasoplegic shock. Current treatment guidelines recommend hemodialysis and supportive care. However, this case report...
3.
Deenen S, Fransen L, Jaspers T, Workum J
Fundam Clin Pharmacol
. 2023 May;
37(5):1011-1015.
PMID: 37161707
Augmented renal clearance (ARC) is a pathophysiological phenomenon that can occur in critically ill patients, leading to enhanced renal function. It is defined as a creatinine clearance of >130 mL/min/1.73 ...
4.
Jaspers T, Meijer C, Vleming L, Franssen C, Diepstraten J, Lukens M, et al.
Clin Pharmacokinet
. 2022 Aug;
61(11):1559-1569.
PMID: 36040615
Introduction: The optimal nadroparin dose in patients undergoing hemodialysis is difficult to determine in clinical practice. Anti-Xa levels ≥ 0.4 IU/mL and < 2.0 IU/mL are suggested to prevent thrombus...
5.
van Uden R, van den Broek M, Houtenbos I, Jaspers T, Harmsze A, Kingma H, et al.
Eur J Clin Pharmacol
. 2021 Jul;
77(12):1919-1926.
PMID: 34319470
Purpose: Treatment schedules for antithrombotic therapy are complex, and there is a risk of inappropriate prescribing or continuation of antithrombotic therapy beyond the intended period of time. The primary aim...
6.
Sun F, Jaspers T, van Hasselt P, Hennink W, van Nostrum C
Pharm Res
. 2016 Jun;
33(9):2168-79.
PMID: 27245464
Purpose: To develop a stable micellar formulation of vitamin K for oral delivery, because the commercial and clinically used formulation of vitamin K (Konakion® MM) destabilizes at gastric pH resulting...